1. Home
  2. DSY vs SKYE Comparison

DSY vs SKYE Comparison

Compare DSY & SKYE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

DSY

Big Tree Cloud Holdings Limited Ordinary Shares

HOLD

Current Price

$4.34

Market Cap

21.8M

Sector

N/A

ML Signal

HOLD

Logo Skye Bioscience Inc.

SKYE

Skye Bioscience Inc.

HOLD

Current Price

$0.70

Market Cap

24.7M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
DSY
SKYE
Founded
2020
2012
Country
China
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
21.8M
24.7M
IPO Year
2023
2013

Fundamental Metrics

Financial Performance
Metric
DSY
SKYE
Price
$4.34
$0.70
Analyst Decision
Strong Buy
Analyst Count
0
3
Target Price
N/A
$15.00
AVG Volume (30 Days)
4.4M
117.5K
Earning Date
01-01-0001
05-08-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
$16.48
N/A
Revenue Growth
N/A
N/A
52 Week Low
$0.17
$0.57
52 Week High
$19.90
$4.99

Technical Indicators

Market Signals
Indicator
DSY
SKYE
Relative Strength Index (RSI) 57.57 46.91
Support Level $1.88 $0.69
Resistance Level $19.90 $0.84
Average True Range (ATR) 0.48 0.04
MACD 0.07 0.00
Stochastic Oscillator 73.53 49.18

Price Performance

Historical Comparison
DSY
SKYE

About DSY Big Tree Cloud Holdings Limited Ordinary Shares

Big Tree Cloud Holdings Ltd is a consumer-oriented, mission-driven, and technology-empowered company engaged in the development, production, distribution, and sales of personal care products and other consumer goods. Operating under a consumer-to-manufacturer and merchant (C2M) model, the company integrates online and offline operations to enhance customer engagement, product innovation, and marketing efficiency. Specializing in feminine hygiene products such as sterilized feminine pads, menstrual pants, and related items, Big Tree Cloud leverages its platform to consolidate resources within China's personal care industry while building a consumer community that provides direct feedback and product insights.

About SKYE Skye Bioscience Inc.

Skye Bioscience Inc is a pre-clinical pharmaceutical company located in San Diego, California. The company's clinical assets focus on the modulation of cannabinoid receptor 1 ("CB1") to provide novel treatments and alternatives for diseases caused by metabolic disorders, inflammation, fibrosis, and neurodegeneration, such as obesity and glaucoma. The company's Phase 2 clinical candidates include nimacimab, a negative allosteric modulating antibody that inhibits peripheral CB1 receptors, currently being developed for the treatment of obesity and SBI-100 Ophthalmic Emulsion ("SBI-100 OE"), a CB1 agonist (activator), currently being developed for the treatment of glaucoma and ocular hypertension.

Share on Social Networks: